HealthEquity (NASDAQ:HQY) Issues FY 2027 Earnings Guidance

Posted by Francis Steltz on Aug 28th, 2026

HealthEquity (NASDAQ:HQY – Get Free Report) updated its FY 2027 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.660-4.730 for the period, compared to the consensus estimate of 4.560. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded HealthEquity from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Barrington Research reiterated an “outperform” rating and issued a $110.00 price objective on shares of HealthEquity in a research report on Friday, May 22nd. Citigroup reissued a “market outperform” rating on shares of HealthEquity in a report on Friday. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a research note on Tuesday, May 26th. Finally, Royal Bank Of Canada raised their target price on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $110.93.

Get Our Latest Research Report on HQY

HealthEquity Stock Down 10.6%

NASDAQ:HQY opened at $93.39 on Friday. HealthEquity has a 12-month low of $72.76 and a 12-month high of $107.62. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $7.81 billion, a P/E ratio of 34.98, a P/E/G ratio of 1.76 and a beta of 0.21. The stock’s fifty day simple moving average is $97.93 and its 200-day simple moving average is $87.81.

HealthEquity (NASDAQ:HQY – Get Free Report) last announced its quarterly earnings data on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.05. The business had revenue of $350.73 million during the quarter, compared to analysts’ expectations of $349.22 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.HealthEquity’s revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Equities research analysts expect that HealthEquity will post 3.92 earnings per share for the current year.

Insider Transactions at HealthEquity

In other news, Director Adrian T. Dillon sold 7,632 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the sale, the director directly owned 62,395 shares of the company’s stock, valued at $6,527,140.95. This represents a 10.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total transaction of $234,650.00. Following the completion of the sale, the executive vice president owned 56,643 shares in the company, valued at $5,381,085. This represents a 4.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 12,456 shares of company stock worth $1,256,664. Company insiders own 1.60% of the company’s stock.

Trending Headlines about HealthEquity

Here are the key news stories impacting HealthEquity this week:

Positive Sentiment: HealthEquity reported quarterly EPS of $1.24, ahead of the $1.19 consensus estimate, while revenue reached $350.7 million, slightly above expectations. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and adjusted EBITDA increasing 11% to $167 million. Net and adjusted EBITDA margins also expanded, indicating operating leverage. HealthEquity Second-Quarter Financial Results
Positive Sentiment: Management raised fiscal 2027 EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion further support the company’s long-term growth prospects. HealthEquity Raises Fiscal 2027 Guidance
Neutral Sentiment: Fiscal 2027 revenue guidance was approximately $1.4 billion, broadly in line with expectations. This suggests the guidance upgrade was driven mainly by improved earnings outlook rather than a meaningful increase in projected sales.
Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares for approximately $798,000, reducing his holdings by 10.9%. The sale was made under a pre-arranged Rule 10b5-1 plan, which limits its bearish signal, but it may still contribute to near-term selling pressure. HealthEquity Director Stock Sale
Negative Sentiment: HQY trades at roughly 35 times earnings after approaching its 52-week high. Investors may be taking profits or demanding stronger upside after the earnings beat, particularly because revenue guidance was not raised significantly.

Institutional Investors Weigh In On HealthEquity

Several hedge funds have recently bought and sold shares of HQY. Acumen Wealth Advisors LLC bought a new position in shares of HealthEquity during the fourth quarter worth $27,000. Aster Capital Management DIFC Ltd bought a new stake in shares of HealthEquity in the 4th quarter valued at $28,000. Caitong International Asset Management Co. Ltd raised its stake in HealthEquity by 1,723.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $28,000 after buying an additional 293 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in HealthEquity by 190.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 604 shares of the company’s stock worth $55,000 after buying an additional 396 shares during the period. Finally, Larson Financial Group LLC lifted its holdings in HealthEquity by 24.4% during the third quarter. Larson Financial Group LLC now owns 628 shares of the company’s stock worth $60,000 after acquiring an additional 123 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Company Profile

(Get Free Report)

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.